Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase RegistryAnnamaria Brioli, Michael Lauseker, Ulla Olsson‐Strömberg et al.|Leukemia|2024Cited by 25
Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis RegistryAnnamaria Brioli, Michael Lauseker, Elza Lomaia et al.|Blood|2022Cited by 3
Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) RegistryJoanna Góra-Tybor, Krzysztof Jamroziak, Aleksandra Gołoś et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 2
Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) RegistryJoanna Góra‐Tybor, Krzysztof Jamroziak, Aleksandra Gołoś et al.|Blood|2019Cited by 0